GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reissued by stock analysts at Deutsche Bank AG in a research note issued on Tuesday. They presently have a GBX 1,720 ($22.41) target price on the stock. Deutsche Bank AG’s price objective points to a potential upside of 7.80% from the company’s previous close.
Other analysts have also issued reports about the company. HSBC Holdings plc reaffirmed a “buy” rating and set a GBX 1,970 ($25.66) target price on shares of GlaxoSmithKline plc in a research report on Thursday, April 27th. Liberum Capital reaffirmed a “buy” rating and set a GBX 1,900 ($24.75) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, April 26th. Jefferies Group LLC dropped their target price on GlaxoSmithKline plc from GBX 1,850 ($24.10) to GBX 1,800 ($23.45) and set a “buy” rating on the stock in a research report on Thursday, April 20th. Beaufort Securities reaffirmed a “buy” rating and set a GBX 1,750 ($22.80) target price on shares of GlaxoSmithKline plc in a research report on Thursday, April 27th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 1,900 ($24.75) target price on GlaxoSmithKline plc and gave the stock a “buy” rating in a research report on Thursday, April 27th. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,732.78 ($22.57).
GlaxoSmithKline plc (GSK) opened at 1598.50 on Tuesday. The stock’s 50 day moving average price is GBX 1,659.19 and its 200 day moving average price is GBX 1,628.96. GlaxoSmithKline plc has a 52-week low of GBX 1,446.50 and a 52-week high of GBX 1,745.56. The firm’s market capitalization is GBX 78.10 billion.
In other GlaxoSmithKline plc news, insider Patrick Vallance acquired 861 shares of GlaxoSmithKline plc stock in a transaction dated Friday, July 14th. The stock was acquired at an average cost of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). Also, insider Victoria Whyte sold 4,820 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of GBX 1,693 ($22.06), for a total value of £81,602.60 ($106,308.75). Over the last quarter, insiders have bought 1,218 shares of company stock valued at $1,959,447.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
